Does J9601 require prior authorization?

Yes, J9601 requires prior authorization (high confidence). At least one active policy explicitly requires prior authorization.

What is the Medicare reimbursement rate for J9601?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

Prior Auth Required

At least one active policy explicitly requires prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Indicated for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

ARKBLUE-LINVOSELTAMAB-GCPT-E-G-LYNOZYFIC-EBB11AF5FD, Linvoseltamab-gcpt (e.g., Lynozyfic)

BCBSM-2201126-54B719E3F4, LYNOZYFIC (LINVOSELTAMAB-GCPT)

POINT32HEALTH-MDMNG-24871, Lynozyfic (linvoseltamab-gcpt)

MULTI

POINT32HEALTH-MDMNG-24486, Lynozyfic (linvoseltamab-gcpt)

MULTI

HEALTHNET_OR-HNOR-LINVOSELTAMAB-GCPT-LYNOZYFIC-CP-PHAR-743-2D1A06FC08, Linvoseltamab-gcpt (Lynozyfic); CP.PHAR.743

MODA-LYNOZYFIC-AE2E0E7910, Lynozyfic (linvoseltamab-gcpt)

IBX-MEDICARE-ADVANTAGE-MA08-188B-15CDDFF061, Linvoseltamab-gcpt (Lynozyfic)

IBX-COMMERCIAL-08-02-47B-84C7F5DCBC, linvoseltamab-gcpt (Lynozyfic)

BCBSTN-9f912eae02, Linvoseltamab-gcpt (Lynozyfic)

EVICORE-HPLAN-HEALTH_PARTNERS_PLANS-4BC80209CCC5, Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List

AMERIHEALTH-COMMERCIAL-08-02-47B-85FA4CF031, linvoseltamab-gcpt (Lynozyfic)

AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-188B-6C7FDFA808, Linvoseltamab-gcpt (Lynozyfic)

EVICORE-HPLAN-CIGNA-729A536F50C8, Q3 - 2026 Cigna MedOnc Master Drug List.pdf

Ask Backwork about documentation requirements, denial risks, or coverage in your state.